India’s biotechnology landscape is undergoing a transformative leap. Bolstered by inclusive policies like BioE3 (for economy, environment, and employment) and Bio-RIDE, the bioeconomy has exploded from $10 billion in 2014 to nearly $166 billion in 2024 on track to reach $300 billion by 2030.
The catalyst for this growth? A surge in innovation-led startups from around 50 a decade ago to nearly 9,000–11,000 today backed by institutional support from DBT, BIRAC, and PLI schemes.
India is now shifting from generics toward biosimilars, monoclonal antibodies, cell & gene therapies, mRNA platforms, and domestically-developed CAR-T treatments. With 49% of the sector driven by biopharma valued at $39 billion in 2021 this evolution is reshaping our global role.
Post a comment
When the machine says no : AI’s risks in finance!
AI speeds financial operations, but unseen dangers bias, exclusion, opacity, accountability gaps—could erode trust and...
Meta enables Business-AI chat on external sites!
Meta is rolling out “Business AI” assistants that companies can embed into their websites and...
Masin AI turns construction dispute cure into prevention!
Masin AI, built by an expert dispute consultancy, uses generative AI to flag contract risks...
When Apps turned policy : India’s geo-national tech rule!
The TikTok saga reflects India’s move from open internet models to sovereign control over data,...
